GLTPD1 Inhibitors
Chemical inhibitors of GLTPD1 include a variety of compounds that impact the lipid transfer activity of this protein by competing with its natural substrates or altering sphingolipid metabolism. D-erythro-Sphingosine, another sphingolipid, can also inhibit GLTPD1 due to its structural resemblance to the protein's natural substrates, effectively blocking the lipid transfer process by occupying the protein's binding sites.
Further inhibitory effects on GLTPD1 can be achieved through the modulation of sphingolipid metabolism. Compounds such as Fumonisin B1 and Myriocin reduce the synthesis of ceramide by inhibiting enzymes like ceramide synthase and serine palmitoyltransferase, respectively. This leads to a lower availability of ceramide for GLTPD1, thus indirectly inhibiting its activity. GW4869 and Imipramine, both inhibitors of sphingomyelinases, alter the sphingolipid balance by increasing sphingomyelin and decreasing ceramide levels, which in turn inhibits GLTPD1 by limiting its substrate pool. PDMP, by inhibiting glucosylceramide synthase, decreases the concentration of glycosphingolipids, thereby reducing the substrates available for GLTPD1 and inhibiting its lipid transfer function. Additionally, compounds like Progesterone and Cyclophosphamide, which induce changes in lipid metabolism, and Desipramine, which inhibits acid sphingomyelinase activity, can all lead to a reduction in the substrates required for GLTPD1 function, thereby inhibiting its activity within the cell.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
D-erythro-Sphingosine | 123-78-4 | sc-3546 sc-3546A sc-3546B sc-3546C sc-3546D sc-3546E | 10 mg 25 mg 100 mg 1 g 5 g 10 g | $88.00 $190.00 $500.00 $2400.00 $9200.00 $15000.00 | 2 | |
D-erythro-Sphingosine can inhibit GLTPD1 by mimicking the natural sphingolipid substrates of GLTPD1, potentially competing for the lipid transfer domain and thereby inhibiting the protein's transfer activity. | ||||||
Fumonisin B1 | 116355-83-0 | sc-201395 sc-201395A | 1 mg 5 mg | $117.00 $469.00 | 18 | |
Fumonisin B1 inhibits ceramide synthase, which can lower the levels of ceramide. Since ceramide is a natural glycolipid substrate for GLTPD1, the reduced availability of ceramide can functionally inhibit GLTPD1's activity by limiting its substrate. | ||||||
Myriocin (ISP-1) | 35891-70-4 | sc-201397 | 10 mg | $106.00 | 8 | |
Myriocin is an inhibitor of serine palmitoyltransferase, the first enzyme in sphingolipid biosynthesis. By reducing the overall sphingolipid pool, myriocin can decrease the substrate availability for GLTPD1, leading to its functional inhibition. | ||||||
GW4869 | 6823-69-4 | sc-218578 sc-218578A | 5 mg 25 mg | $199.00 $599.00 | 24 | |
GW4869 is a non-competitive inhibitor of neutral sphingomyelinase, which can lead to an increase in sphingomyelin and a decrease in ceramide levels. Since ceramide is a substrate for GLTPD1, the alteration of sphingolipid metabolism can result in a functional inhibition of GLTPD1 by reducing the availability of its substrate. | ||||||
Imipramine hydrochloride | 113-52-0 | sc-207753 sc-207753B sc-207753A | 100 mg 1 g 5 g | $25.00 $44.00 $101.00 | 5 | |
Imipramine, a tricyclic antidepressant, can also inhibit acid sphingomyelinase. The reduction in sphingomyelinase activity can increase sphingomyelin and decrease ceramide levels. Since GLTPD1 requires ceramide among its substrates, imipramine can functionally inhibit GLTPD1 by altering the balance of sphingolipids available for transfer. | ||||||
Progesterone | 57-83-0 | sc-296138A sc-296138 sc-296138B | 1 g 5 g 50 g | $20.00 $51.00 $292.00 | 3 | |
Progesterone has been shown to modulate sphingolipid metabolism. By influencing the levels of sphingolipids, progesterone can indirectly affect the substrate availability for GLTPD1, leading to functional inhibition of the protein's lipid transfer capabilities. | ||||||
Cyclophosphamide | 50-18-0 | sc-361165 sc-361165A sc-361165B sc-361165C | 50 mg 100 mg 500 mg 1 g | $76.00 $143.00 $469.00 $775.00 | 18 | |
Cyclophosphamide, an alkylating agent, can induce alterations in lipid metabolism. These alterations can influence the sphingolipid biosynthetic pathway and potentially reduce the availability of substrates for GLTPD1, thus functionally inhibiting its activity. | ||||||
Desipramine hydrochloride | 58-28-6 | sc-200158 sc-200158A | 100 mg 1 g | $65.00 $115.00 | 6 | |
Desipramine, another tricyclic antidepressant, similarly inhibits acid sphingomyelinase. By decreasing acid sphingomyelinase activity, it can lead to increased sphingomyelin and decreased ceramide levels, which can functionally inhibit GLTPD1 by reducing the pool of ceramide for the protein to transfer. | ||||||